Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter

Clinical Research in Cardiology

Volumn 101, Issue 6, 2012, Pages 469-476

  Cremers, Bodo ^a   Toner, John L ^b   Schwartz, Lewis B ^b   Von Oepen, Randolf ^b   Speck, Ulrich ^c   Kaufels, Nicola ^c   Clever, Yvonne P ^a   Mahnkopf, Dirk ^d   Böhm, Michael ^a   Scheller, Bruno ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ABBOTT LABORATORIES   (United States)

^c HUMBOLDT UNIVERSITY   (Germany)

^d IMTR GmbH   (Germany)

Author keywords

Angioplasty; Drug coated balloon; Drug eluting stent; Restenosis; Zotarolimus

Indexed keywords

ZOTAROLIMUS;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BALLOON CATHETER; CONTROLLED STUDY; CORONARY ARTERY; DRUG COATED BALLOON CATHETER; DRUG ELUTING STENT; HISTOPATHOLOGY; HYPERPLASIA; INTERMETHOD COMPARISON; MATERIAL COATING; NEOINTIMA; NONHUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SAFETY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SWINE; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CORONARY RESTENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; HYPERPLASIA; NEOINTIMA; SIROLIMUS; SWINE;

EID: 84863720353     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-012-0415-7     Document Type: Article

References (30)

1. De Labriolle A, Pakala R, Bonello L, Lemesle G, Scheinowitz M, Waksman R (2009) Paclitaxel-eluting balloon: from bench to bed. Catheter Cardiovasc Interv 73:643-652
2. Waksman R, Pakala R (2009) Drug-eluting balloon: the comeback kid? Circ Cardiovasc Interv 2:352-358
3. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G (2004) Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110:810-814
4. Cremers B, Biedermann M, Mahnkopf D, Böhm M, Scheller B (2009) Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol 98:325-330
5. Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Böhm M, Hamm B (2006) Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drugeluting stent in porcine coronary arteries. Radiology 240:411-418
6. Cremers B, Speck U, Kaufels N, Mahnkopf D, Kühler M, Böhm M, Scheller B (2009) Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost 101:201-206
7. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113-2124
8. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U (2008) Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 97:773-781
9. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119:2986-2994
10. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U (2008) Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 358:689-699
11. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J (2008) Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 118:1358-1365
12. Garcia-Touchard A, Burke SE, Toner JL, Cromack K, Schwartz RS (2006) Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 27:988-993
13. Abizaid A, Lansky AJ, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, Mattos L, Abizaid A, Chaves A, Centemero M, Sousa AG, Sousa JE, Zaugg MJ, Schwartz LB (2007) Percutaneous coronary revascularization using a trilayer metal phosphorylcholine- coated zotarolimus-eluting stent. Am J Cardiol 99:1403-1408
14. Lasave LI, Costa Jde R Jr, Abizaid AA, Feres F, Tanajura LF, Staico R, Abizaid AA, Beraldo P, Sousa AM, Sousa JE (2007) A three-dimensional intravascular ultrasound comparison between the new zotarolimus-eluting stent (ZoMaxx) and the non-drugeluting TriMaxx stent. J Invasive Cardiol 19:303-308
15. Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB, ZoMaxx I Investigators (2008) A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus-versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries. The ZoMaxx I trial. JACC Cardiovasc Interv 1:524-532
16. Cromack KR, Xu X, Peykova D, Palwai S (2005) Physicochemical profiling of drug compounds for drug-eluting stents, ABT-578, rapamycin, paclitaxel, and other drugs. CRT, Abstract 501
17. Abizaid A, Popma JJ, Tanajura LF, Hattori K, Solberg B, Larracas C, Feres F, Costa Jde R Jr, Schwartz LB (2007) Clinical and angiographic results of percutaneous coronary revascularization using a trilayer stainless steel-tantalum-stainless steel phosphorylcholine- coated stent: the TriMaxx trial. Catheter Cardiovasc Interv 70:914-919
18. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR (1992) Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 19:267-274
19. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB (1998) In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 31:224-230
20. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, TAXUS-IV Investigators (2004) A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. N Engl J Med 350:221-231
21. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, SIRIUS Investigators (2003) Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323
22. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Boone E, Miquel- Herbert K, Daemen J (2006) A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Eurointervention 2:286-294
23. Fajadet J, Wijns W, Laarman G-J, Kuck K-H, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE (2006) Randomized, doubleblind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the Endeavor II trial. Circulation 114:798-806
24. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372:1163-1173
25. Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo H (2006) Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol 58:665-672
26. Ranade SV, Miller KM, Richard RE, Chan AK, Allen MJ, Helmus NM (2004) Physical characterization of controlled release of paclitaxel from TaxusTMExpress2TM drug-eluting stent. J Biomed Mater Res 71A:625-634
27. Burke SE, Kuntz RE, Schwartz LB (2006) Zotarolimus (ABT- 578) eluting stents. Adv Drug Deliv Rev 58:437-446
28. Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, Kaluza GL, Chronos NAF, Robinson KA, Waksman R, Weinberger J, Wilson GJ, Wilensky RL (2008) Drug-eluting stents in preclinical studies Update consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv 1:143-153
29. DuVall M, Qin JI, Clifford A, Barry CM, Nowak SA, Sabaj KM, Zielinski DA, Smits G, Zhang J, Cromack K, Dube H, Schwartz LB, Krasula RW (2004) ABT-578 elution profile and arterial penetration using the ZOMAXX drug-eluting stent. Am J Cardiol 94:6E
30. Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O (2004) Inhibition of restenosis in stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media. Invest Radiol 39:182-186